Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease
Launched by ASSOCIATION HGE CHU BORDEAUX SUD · Feb 11, 2014
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well non-invasive methods, like blood tests and imaging, can help doctors predict the long-term outcomes for patients with chronic liver disease. Specifically, the study aims to see how well these methods can forecast survival and potential complications related to cirrhosis, a serious condition that can arise from chronic liver disease. The trial is currently recruiting participants aged 65 to 74, and it is open to individuals with chronic hepatitis B, chronic hepatitis C, alcohol-related liver disease, or non-alcoholic liver disease.
If you qualify and choose to participate, you will help researchers gather important information that could improve how chronic liver disease is diagnosed and managed in the future. It’s worth noting that individuals with ascites, which is fluid buildup in the abdomen, are not eligible for this study. Overall, this trial is a valuable opportunity to contribute to a better understanding of liver disease and its impact on health over time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • chronic hepatitis C
- • chronic hepatitis B
- • alcohol liver disease
- • non alcoholic liver disease
- Exclusion Criteria:
- • ascitis
About Association Hge Chu Bordeaux Sud
The Association Hôpital Général Européen (HGE) at CHU Bordeaux Sud is a prominent clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative therapeutic interventions. Located in Bordeaux, France, this institution collaborates with multidisciplinary teams of healthcare professionals and researchers to design, implement, and oversee clinical trials across various therapeutic areas. Committed to upholding the highest ethical standards and regulatory compliance, HGE CHU Bordeaux Sud plays a vital role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of care provided to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pessac, , France
Patients applied
Trial Officials
Juliette Foucher, MD
Study Chair
Association HGE CHU Bordeaux Sud
Faiza Chermak, MD
Study Chair
Association HGE CHU Bordeaux Sud
Victor de Lédinghen, MD, PhD
Study Director
Association HGE CHU Bordeaux Sud
Jean-Baptiste Hiriart, MD
Study Chair
Association HGE CHU Bordeaux Sud
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials